Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsSTU:4DN +4.78%39 EBITDA Margin % is -3,497.99% as of Jun. 2026. GuruFocus rates STU:4DN with a GF Score™ of 39/100 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, Denali Therapeutics ranks worse than 94.92% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Denali Therapeutics's EBITDA for the
three
months ended in Jun. 2026 was €-109.42 Mil. Denali Therapeutics's Revenue for the
three
months ended in Jun. 2026 was €3.13 Mil. Therefore, Denali Therapeutics's EBITDA margin for the quarter that ended in Jun. 2026 was -3,497.99%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Denali Therapeutics EBITDA Margin % Related Terms
Denali Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4DN vs RCUS, ALMS, ELVN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Denali Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (STU:4DN) has a EBITDA Margin % of -3,497.99% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Denali Therapeutics and its competitors. According to the industry distribution chart, Denali Therapeutics ranks #896 out of 944 companies in the Biotechnology industry, placing it in the top 94.9%.
Is Denali Therapeutics' EBITDA Margin % too high?
Denali Therapeutics' current EBITDA Margin % is -3,497.99%. Based on the distribution chart, Denali Therapeutics ranks #896 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Denali Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' EBITDA Margin % compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #896 out of 944 companies for EBITDA Margin %. This places Denali Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Denali Therapeutics and its competitors. Denali Therapeutics's current EBITDA Margin % is -3,497.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Denali Therapeutics (STU:4DN) is currently considered Significantly Overvalued. The current EBITDA Margin % is -3,497.99%. Denali Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Denali Therapeutics (STU:4DN), the current EBITDA Margin % is -3,497.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
39GF Score
Get the complete analysis for STU:4DN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4DN has been successfully added to your 
